ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
The prognostic value of peripheral hematological biomarkers in patients with hypersensitivity pneumonitis: A single-center retrospective study.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimInvestigating inflammation-related biomarkers in hypersensitivity pneumonitis (HP) patients may provide valuable insights, particularly in determining their clinical course and prognosis. This study aimed to explore the potential role of peripheral hematological biomarkers in predicting the clinical course and prognosis of HP patients. MATERIALS AND
methodsThis retrospective study included 75 patients diagnosed with HP. Demographic data, symptoms, exposure history, pulmonary function tests, systemic immune-inflammation index (SII), and aggregate index of systemic inflammation (AISI) were analyzed.
resultsElevated SII (1353.6±915.15) and AISI (1001.1±695.38) values were significantly higher in patients with fibrotic HP compared to non-fibrotic HP (SII: 607.84±334.53, AISI: 375.01±235.18) (p<0.001). ROC analysis showed that SII (cut-off: 644.9, AUC: 0.788) and AISI (cut-off: 438.79, AUC: 0.767) had good predictive value for fibrotic HP. For mortality, SII ≥690.12 (AUC: 0.736) and AISI ≥490.35 (AUC: 0.753) were significant predictors. These elevated values were also associated with higher mortality (46.3% vs. 8.8%, p=0.001 for SII, and 42.5% vs. 14.3%, p=0.004 for AISI). In univariate analysis, older age, digital clubbing, low FVC%, and high SII/AISI were associated with fibrotic HP, while multivariate analysis identified only increased SII (OR: 1.45, p=0.021) and reduced FVC% (OR: 0.999, p=0.043) as independent predictors.
conclusionSII and AISI appear as valuable prognostic tools in determining the clinical course and prognosis of HP patients. These biomarkers could be beneficial in the early diagnosis and management of HP, offering high sensitivity and specificity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.